Vor Bio, founded by famed cancer biologist Siddhartha Mukherjee, is looking for a way out. Its decision to pursue strategic ...

Fyodor Urnov and Kiran Musunuru advocate for streamlined CRISPR treatments for rare genetic diseases, partnering with Danaher ...

After working off $20 million in seed funding for about four years, HAYA Therapeutics tapped the funding well and came back ...

Lan­theus fi­nal­ly came clean about the fate of its ex­per­i­men­tal ra­dio­phar­ma­ceu­ti­cal for prostate can­cer, ...

President Trump met with pharma CEOs at the White House. After praising investments, a 'most favored nation' drug pricing ...

The FDA announced a two-day meeting of its Oncologic Drugs Advisory Committee (ODAC) later this month to review cancer drugs ...

Gilead is the latest drugmaker to announce that it’s pouring billions of dollars into its manufacturing and R&D operations in ...

Vinay Prasad named to replace Peter Marks as head of FDA's Center for Biologics Evaluation and Research; discussion planned ...

CRISPR Therapeutics has revealed promising but early data from its first clinical study of a gene editing therapy to lower ...

Federal appeals court overturns order blocking Avadel Pharmaceuticals from seeking FDA approval for Lumryz in idiopathic ...

Charles River Laboratories is set to start a strategic review and add four new board members after it settled on a ...

NewAmsterdam's obicetrapib reduced Lp(a) by 45% in Phase 3; C4 Therapeutics advances cemsidomide while dropping CFT1946; Vivo ...